Therapeutic strategies against COVID-19

Main Article Content

Susanna Esposito
Margherita Gnocchi
Martina Gagliardi
Paola Affanni
Licia Veronesi
Maria Eugenia Colucci
Cosimo Neglia
Alberto Argentiero
Nicola Principi

Keywords

antiviral drug;, COVID-19, drug repurposing, immunomodulatory drug, SARS-CoV-2

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that mainly affects the upper and lower respiratory tract and is responsible for extremely different degrees of disease, ranging from flu-like symptoms to atypical pneumonia that may evolve to acute respiratory distress syndrome and, ultimately, death. No specific therapy for SARS-CoV-2 has yet been identified, but since the beginning of the outbreak, several pre-existing therapeutics have been reconsidered for the treatment of infected patients. The aim of this article is to discuss current therapeutics against SARS-CoV-2. A literature review was performed using PubMed, collecting data from English-language articles published until June 20th, 2020. Literature analysis showed that with the acquisition of more in-depth knowledge on the characteristics of SARS-CoV-2 and the pathogenesis of the different clinical manifestations, a more rationale use of available drugs has become possible. However, the road to defining which drugs are effective and which schedules of administration must be used to maximize efficacy and minimize adverse events is still very long. To date, it is only clear that no drug can alone cope with all the problems posed by SARS-CoV-2 infection and effective antivirals and inflammatory drugs must be given together to reduce COVID-19 clinical manifestations. Moreover, choice of therapy must always be tailored on clinical manifestations and, when they occur, drugs able to fight coagulopathy and venous thromboembolism that may contribute to respiratory deterioration must be prescribed. 

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...
Abstract 57 | PDF Downloads 32

References

1) Elshabrawy HA. SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries. Vaccines (Basel). 2020;8:E335.
2) Morse JS, Lalonde T, Xu S, Liu WR. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chem Bio Chem 2020;21:730-738.
3) Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Version 2. Acta Pharm Sin B. 2020;10:766-788.
4) Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 2020;20:363–374.
5) Zhang Y, He L, Chen H, Lu S, Xiong Y, Liu J, et al. Manifestations of blood coagulation and its relation to clinical outcomes in severe COVID-19 patients: Retrospective analysis. Int J Lab Hematol. 2020; Epub Jun 27.
6) Abraham, J. Passive antibody therapy in COVID-19. Nat Rev Immunol 2020;20:401–403.
7) Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents 2020;55:105923.
8) Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis 2003;3:722-727.
9) Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 2007;30:297-308.
10) Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020;16:155-166.
11) Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect Dis 2006;6:67–69.
12) Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271.
13) Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;9:ciaa237.
14) Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;18:16.
15) Quiros Roldan E, Biasiotto G, Magro P, Zanella I. The possible mechanisms of action of 4-aminoquinolines chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? Pharmacol Res. 2020;158:104904.
16) Huang M, Tang T, Pang P, Li M, Ma R, Lu J, et al. Treating COVID-19 with chloroquine. J Mol Cell Biol. 2020;12:322-325.
17) Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID‐19 patients with at least a six‐day follow up: a pilot observational study. Travel Med Infect Dis 2020;34:101663
18) Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID‐ 19: results of an open‐label non‐randomized clinical trial. Int J Antimicrob Agents 2020;105949 10.1016/j.ijantimicag.2020.105949.
19) National Health Commission of the People's Republic of China Interpretation of COVID‐19 Treatment Guidelines (6th version). Available at: http://www.gov.cn/zhengce/2020-02/19/content_5480958.htm. Accessed: June 17, 2020.
20) Hinton DM. Request for Emergency Use Authorization For Use of Chloroquine Phosphate or Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of 2019 Coronavirus Disease. US FDA; Available at: http://www.fda.gov/media/136534/download. Accessed: June 18, 2020.
21) Dos Reis Neto ET, Kakehasi AM, de Medeiros Pinheiro M, Ferreira GA, Marques CDL, da Mota LMH, et al. Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Adv Rheumatol. 2020;60:32.
22) . Sarma P, Kaur H, Kumar H, Mahendru D, Avti P, Bhattacharyya A, et al. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. J Med Virol 2020;92:776-785.
23) World Health Organization. “Solidarity” Clinical Trial for COVID-19 treatmentes. Available at. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments Accessed on: June 20, 2020.
24) Recovery. Randomised evaluation of COVID-19 therapy. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. Available at: https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19 Accessed on: June 18, 2020.
25) Mahase E. Hydroxychloroquine for covid-19: the end of the line? BMJ 2020;369:m2378.
26) US Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and Accessed on: June 18, 2020.
27) AIFA. Agenzia Italiana del Farmaco. Home Emergenza COVID-19 AIFA sospende l’autorizzazione all’utilizzo di idrossiclorochina per il trattamento del COVID-19 al di fuori degli studi clinici. Available at: https://www.aifa.gov.it/web/guest/-/aifa-sospende-l-autorizzazione-all-utilizzo-di-idrossiclorochina-per-il-trattamento-del-covid-19-al-di-fuori-degli-studi-clinici Accessed on: June 18, 2020.
28) Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020; Epub May 22. doi: 10.1016/S0140-6736(20)31180-6.
29) Mehra MR, Ruschitzka F, Patel AN. Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020; Epub Jun 5 doi: 10.1016/S0140-6736(20)31324-6.
30) Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020; Epub Jun 3. 10.1056/NEJMoa2016638. doi:10.1056/NEJMoa2016638.
31) Agrawal S, Goel AD, Gupta N. Emerging prophylaxis strategies against COVID-19. Monaldi Arch Chest Dis. 2020;90:10.4081/monaldi.2020.1289.
32) Arnold SLM, Buckner F. Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection [published online ahead of print, 2020 Apr 8]. Clin Transl Sci. 2020;10.1111/cts.12797.
33) Savarino A, Tarek M. Pharmacokinetic bases of the hydroxychloroquine response in COVID-19: implications for therapy and prevention medRxiv 2020.04.23.20076471; doi: https://doi.org/10.1101/2020.04.23.20076471.
34) Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016;531:381-385.
35) Lo MK, Jordan R, Arvey A, Sudhamsu J, Shrivastava-Ranjan P, Hotard AL, et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci Rep 2017;7:43395.
36) Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017;28;9:eaal3653.
37) Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020;11:222.
38) Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe A, et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 2016;338:498–503.
39) Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019;381:2293-2303
40) Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020;382:929-936.
41) Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagnaet A et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 2020;382:2327-2336.
42) Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. 2020; Epub May 22. NEJMoa2007764. doi:10.1056/NEJMoa2007764.
43) Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569-1578.
44) Sun D. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit. AAPS J. 2020;22:77. doi:10.1208/s12248-020-00459-8.
45) Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531:381-385.
46) Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020; Epub May 27. 10.1056/NEJMoa2015301. doi:10.1056/NEJMoa2015301.
47) Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5:428-430.
48) Chan KS, Lai ST, Chu CM, Tsui E, Tam CY, Wong MM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 2003;9:399-406.
49) Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, et al.. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 2015;212:1904-1913.
50) Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59:252-256.
51) Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR. J Korean Med Sci 2020;35:e79.
52) Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA 2020; 323:1488-1494.
53) Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with Severe Covid-19. N Engl J Med 382:1787-1799.
54) Osborne, V., Davies, M., Lane, S. Evans A, Denyer J, Dhanda S, et al. Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment. Drug Saf 2020; Epub Jun 23. doi: 10.1007/s40264-020-00966-9.
55) Smolders EJ, Te Brake LH, Burger DM. SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection. Antivir Ther. 2020; Epub Jun 26. doi: 10.3851/IMP3365.
56) Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 2016;15:327-347.
57) Knowles SR, Phillips EJ, Dresser L, Matukas L. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clin Infect Dis 2003;37:1139–1142.
58) Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med 2006;3:e343.
59) AIFA Agenzia Italiana del Farmaco. An Open-label Compassionate Use Study to Evaluate the Safety and Efficacy of VIRAZOLE® (Ribavirin for Inhalation Solution, USP) in Hospitalized Adult Participants with Respiratory Distress Due to SARS-CoV-2 (COVID-19). Available at: https://www.aifa.gov.it/documents/20142/1172315/Ribavirina_documenti.zip Accessed on: June 23, 2020.
60) Government of Canada. Drugs and vaccines for COVID-19: List of authorized clinical trials. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-clinical-trials/list-authorized-trials.html Accessed on: June 23, 2020.
61) Principi N, Camilloni B, Alunno A, Polinori I, Argentiero A, Esposito S. Drugs for Influenza Treatment: Is There Significant News? Front Med (Lausanne) 2019;6:109.
62) Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009;82:95-102.
63) Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 2014;105:17-21.
64) Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-271.
65) Qingxian C, Minghui Y, Dongjing L, Jun C, Dan S, Junxia X, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering 2020; Epub March 18.
66) Khamitov RA, Loginova SIa, Shchukina VN, Borisevich SV, Maksimov VA, Shuster AM. Antiviral Activity of Arbidol and Its Derivatives Against the Pathogen of Severe Acute Respiratory Syndrome in the Cell Cultures. Vopr Virusol 2008;53:9-13.
67) Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect 2020;26:917-921.
68) Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, et al. Interferon-α2b Treatment for COVID-19. Front Immunol 2020;11:1061.
69) Yang C, Ke C, Yue D, Li W, Hu Z, Liu W, Hu S, Wang S, Liu J. Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals. Front Public Health 2020;8:249.
70) Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033-1034.
71) Vázquez-Laslop N, Mankin AS. How Macrolide Antibiotics Work. Trends Biochem Sci 2018;43:668-684.
72) Tran DH, Sugamata R, Hirose T, Suzuki S, Noguchi Y, Sugawara A, et al. Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process. J Antibiot 2009;72:759–768.
73) Min JY, Jang YJ. Macrolide therapy in respiratory viral infections. Mediators Inflamm 2012;2012:649570..
74) Guo D, Cai Y, Chai D, Liang B, Bai N, Wang R. The cardiotoxicity of macrolides: a systematic review. Pharmazie 2010;65:631-640.
75) Dagens A, Sigfrid L, Cai E, Lipworth S, Cheng V, Harriset E, et al. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review. BMJ 2020;369:m1936.
76) Corneli HM, Zorc JJ, Mahajan P. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N Engl J Med 2007;357:331–339.
77) Ni YN, Chen G, Sun J, Liang BM, Liang ZA. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care. 2019;23:99.
78) Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am. J. Respir. Crit. Care Med 2018;197:757–767.
79) Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J. Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061-1069.
80) Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395:473–475.
81) Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. medRxiv 2020.06.22.20137273; doi: https://doi.org/10.1101/2020.06.22.20137273.
82) National Health System. Dexamethasone in the treatment of COVID-19: Implementation and management of supply for treatment in hospitals. 2020. Available at: https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103054. Accessed on: June 18, 2020.
83) Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. J Infect 2020;80:607-613.
84) Miao Y, Fan L, Li JY. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids. Front Immunol. 2020;11:1445.
85) Kang S, Tanaka T, Narazaki M, Kishimoto T.Targeting Interleukin-6 Signaling in Clinic. Immunity. 2019;50:1007-1023.
86) Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M, Boffini N, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med 2020;76:43-49.
87) Jordan SC, Zakowski P, Tran HP, et al. Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia. Clin Infect Dis. 2020;ciaa812. doi:10.1093/cid/ciaa812.
88) Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumat 2020; Epub June 24. https://doi.org/10.1016/S2665-9913(20)30173-9
89) Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117:10970-10975.
90) Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev 2020;19:102568.
91) Conrozier T, Lohse A, Balblanc JC, Dussert P, Royer PY, Bossert M, et al. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration. Clin Exp Rheumatol. 2020; Epub June 23.
92) Rojas-Marte GR, Khalid M, Mukhtar O, Hashmi AT, Waheed MA, Ehrlich S, et al. Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab - A Case- Controlled Study. QJM. 2020;hcaa206. doi:10.1093/qjmed/hcaa206
93) Sciascia S, Aprà F, Baffa A, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol 2020;38:529-532..
94) Klopfenstein T, Zayet S, Lohse A, Balblanc JC, Badie J, Royer PY, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect 2020; Epub May 6. doi:10.1016/j.medmal.2020.05.001.
95) Pipeline Review. Tocilizumab improves significantly clinical outcomes of patients with moderate or severe COVID-19 pneumonia. Available on: https://pipelinereview.com/index.php/2020042874458/Antibodies/Tocilizumab-improves-significantly-clinical-outcomes-of-patients-with-moderate-or-severe-COVID-19-pneumonia.html. Accessed on: June 25, 2020.
96) Kewana T, Covuta F, Al-Jaghbeerb MJ, Rosec L, Gopalakrishna KV, et al. Tocilizumab for treatment of patients with severe COVID19: A retrospective cohort study. EClinicalMedicine 2020; https://doi.org/10.1016/j.eclinm.2020.100418
97) A Comprehensive Review on Tocilizumab in COVID‐19 Acute Respiratory Distress Syndrome. J Clin Pharmacol 2020; https://doi.org/10.1002/jcph.1693
98) Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006;145:599-609.
99) Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015;211:80-90.
100) Ko JH, Seok H, Cho SY, Ha YE, Baek JY, Kim SH, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther 2018;23:617-622.
101) Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA 2020;323:1582-1589.
102) Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. PNAS 2020;117:9490-9496.
103) Li L, Zhang W, Hu Y, Tong X, Zheng S, Yanet J. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical. JAMA 2020;e2010044. doi:10.1001/jama.2020.10044.
104) Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MHL, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005;24: 44–46.
105) Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of Coronavirus Disease 2019. Crit Care Med 2020; Epub May 27:10.1097/CCM.0000000000004458. doi: 10.1097/CCM.0000000000004458.
106) Thachil J. The versatile heparin in COVID-19. J Thromb Haemost. 2020;18:1020-1022

Most read articles by the same author(s)